ImmunoMet Therapeutics
Houston
About ImmunoMet Therapeutics
ImmunoMet Therapeutics is a development-stage biopharmaceutical company focused on the development and commercialization of novel oncology products that are aimed to improve the quality of life of cancer patients. With more than 6 years of experience in the field of cancer metabolism and immunometabolism, ImmunoMet has developed a comprehensive pipeline of metabolic regulators preferentially targeting the cellular metabolism of drug-resistant cancer subpopulations and immuno-suppressors of anti-cancer effector T cells.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $17.2M
- Funding stage: Early Stage Venture
- Last round: Series B (Feb 2021)
- Website: immunomet.com
- Phone: +119196161923
Industries & Categories
Biopharma, Biotechnology, Health Care, Oncology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/immunomet-therapeutics-73200 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.